EV/EBITDA Ratio: 54.81x

Basis: Current FMP quote-based enterprise value / four-quarter operating income plus matched D&A. Source: stored company filings and market data; unavailable inputs remain N/A.

Is the EV/EBITDA ratio high or low?

The EV/EBITDA ratio of 54.81x is in line with its estimated 4-year average of 50.26x, near the low end of its estimated 4-year range (23.28x–498.94x).

As of 2026-10-06T16:57:18.522Z. 9.29% below its estimated 12-month average of 60.42x.

KNSA EV/EBITDA Ratio Metrics

EV/EBITDA vs. estimated history

At 54.8, EV/EBITDA is near its estimated 4-year median — higher than 57% of readings in its estimated 4-year history.

Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.

EV/EBITDA Ratio Formula & Definition

EV/EBITDA = Enterprise Value / EBITDA (TTM)

Enterprise value to EBITDA is a capital-structure-neutral valuation multiple, useful for comparing companies with different debt levels and tax rates.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

EV/EBITDA Ratio FAQ

What is the EV/EBITDA ratio for Kiniksa Pharmaceuticals International, plc (KNSA)?

The EV/EBITDA ratio for KNSA stock is 54.81x.

Is Kiniksa Pharmaceuticals International, plc's EV/EBITDA ratio high or low?

The EV/EBITDA ratio of 54.81x is in line with its estimated 4-year average of 50.26x, near the low end of its estimated 4-year range (23.28x–498.94x).

What is the estimated TTM average EV/EBITDA ratio for Kiniksa Pharmaceuticals International, plc (KNSA)?

The estimated TTM average EV/EBITDA ratio for KNSA stock is 60.42x.

What is the estimated 3Y average EV/EBITDA ratio for Kiniksa Pharmaceuticals International, plc (KNSA)?

The estimated 3Y average EV/EBITDA ratio for KNSA stock is 57.47x.

Showing the most recent 260 of 468 data points. The chart above shows the full history.

Related Metrics